Q-linea receives letter of intent to evaluate and potential commercialization of Podler

MAR

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received a Letter of Intent (LOI) for the evaluation and a possible commercialization partnership for Podler with a large market leading company.

The Podler technology is currently under development within Q-linea and could enable a significant improvement in blood culturing for patients with blood infections, of which sepsis is the most severe condition. Podler is a handheld fully autonomous device to incubate and detect growth in blood culture bottles. The technology can make use of valuable transportation time, time which may be wasted when using traditional methods. The use of transportation time could enable much faster time to result for patients with blood infections and provide equal care to patients with severe infections. 

"This is an important step in our strategy for the commercialization of the Podler technology. The traditional blood culturing market is dominated by only a few major companies, and to have early interest in evaluating Podler is of course a very positive first step. It proves the serious interest we are seeing for our technology which is very positive for our future development and long term go to market strategy for Podler,” said Jonas Jarvius, CEO of Q-linea.

Datum 2022-07-06, kl 21:40
Källa MFN
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.